NAMPT inhibition relieves intestinal inflammation by regulating macrophage activation in experimental necrotizing enterocolitis

Biomed Pharmacother. 2023 Sep:165:115012. doi: 10.1016/j.biopha.2023.115012. Epub 2023 Jun 15.

Abstract

Nicotinamide phosphoribosyl transferase (NAMPT) is associated with various NAD+ -consuming enzymatic reactions. The precise role in intestinal mucosal immunity in necrotizing enterocolitis (NEC) is not well defined. Here, we examined whether NAMPT inhibition by the highly specific inhibitor FK866 could alleviate intestinal inflammation during the pathogenesis of NEC. In the present study, we showed that NAMPT expression was upregulated in the human terminal ileum of human infants with NEC. FK866 administration attenuated M1 macrophage polarization and relieved the symptoms of experimental NEC pups. FK866 inhibited intercellular NAD+ levels, macrophage M1 polarization, and the expression of NAD+ -dependent enzymes, such as poly (ADP ribose) polymerase 1 (PARP1) and Sirt6. Consistently, the capacity of macrophages to phagocytose zymosan particles, as well as antibacterial activity, were impaired by FK866, whereas NMN supplementation to restore NAD+ levels reversed the changes in phagocytosis and antibacterial activity. In conclusion, FK866 reduced intestinal macrophage infiltration and skewed macrophage polarization, which is implicated in intestinal mucosal immunity, thereby promoting the survival of NEC pups.

Keywords: FK866; Macrophage; NAD+; NAMPT; NEC.

MeSH terms

  • Cytokines / metabolism
  • Enterocolitis, Necrotizing* / metabolism
  • Humans
  • Infant, Newborn
  • Inflammation / metabolism
  • Macrophage Activation
  • Macrophages / metabolism
  • NAD* / metabolism

Substances

  • Cytokines
  • NAD
  • nicotinamide phosphoribosyltransferase, human